Epha1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
EPHA1 (Ephrin Type-A Receptor 1) encodes a receptor tyrosine kinase that binds ephrin-A ligands. GWAS have identified EPHA1 as a risk gene for Alzheimer's disease. The protein is involved in synaptic plasticity, neuronal development, and immune regulation.
| Property | Value |
|---|---|
| Gene Symbol | EPHA1 |
| Full Name | Eph Receptor A1 |
| Chromosomal Location | 7q34 |
| NCBI Gene ID | 2043 |
| Ensembl ID | ENSG00000146938 |
| UniProt ID | P21709 |
| OMIM | 179610 |
| Property | Value |
|---|---|
| Protein Name | EPHA1 |
| Molecular Weight | ~108 kDa (976 amino acids) |
| Subcellular Localization | Cell membrane, endosomes |
| Protein Family | Ephrin receptor family, tyrosine kinase |
| Approach | Status | Description |
|---|---|---|
| Kinase inhibitors | Research | Targeting EPHA1 kinase activity |
| Ephrin agonists | Research | Activating EPHA1 signaling |
| None direct | — | No current clinical trials for AD |
The study of Epha1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] EPHA1 and Alzheimer disease risk. PMID:21460847
EPHA1 is being investigated as a potential therapeutic target for AD and other neurodegenerative diseases. Modulating EPHA1 signaling could help reduce neuroinflammation and synaptic loss. Antibody-based therapies targeting EPHA1 are in early development.
| Approach | Target | Stage | Indication |
|---|---|---|---|
| EPHA1 agonists | EPHA1 | Discovery | AD |
| EPHA1 antagonists | EPHA1 | Discovery | Cancer |
| Antibody therapy | EPHA1 | Preclinical | AD |
Research on EPHA1 focuses on understanding its role in microglial activation and neuroinflammation in AD. Studies are investigating how EPHA1 genetic variants modify AD risk and disease progression. Additionally, research is exploring the role of EPHA1 in synaptic plasticity and cognitive function.